✦ LIBER ✦

Pharmacokinetics of Intravenous Conivaptan in Subjects With Hepatic or Renal Impairment

✍ Scribed by Michael J. Roy, Keith A. Erdman, Anura T. Abeyratne…

Book ID: 120803245
Publisher: Springer International Publishing AG
Year: 2013
Tongue: English
Weight: 426 KB
Volume: 52
Category: Article
ISSN: 0312-5963
DOI: 10.1007/s40262-013-0047-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of Vandetanib in Subjec

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

✍ Angelika Weil, Dr Paul Martin, Robert Smith, Stuart Oliver, Peter Langmuir, Jess 📂 Article 📅 2010 🏛 Springer International Publishing AG 🌐 English ⚖ 220 KB

Single-dose pharmacokinetics of quetiapi

Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment

✍ Per T Thyrum; Yw James Wong; Chiao Yeh 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 835 KB

Single-Dose Pharmacokinetics of Boceprev

Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function

✍ Dr Michelle Treitel, Thomas Marbury, Richard A. Preston, Ilias Triantafyllou, Wi 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 193 KB

Pharmacokinetics of afatinib in subjects

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

✍ Schnell, David; Buschke, Susanne; Fuchs, Holger; Gansser, Dietmar; Goeldner, Rai 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 389 KB

Pharmacokinetics of insulin aspart in ob

Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment

✍ Gregory Holmes; Lawrence Galitz; Peter Hu; William Lyness 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB

Single-dose pharmacokinetics of nefazodo

Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment

✍ R. H. Barbhaiya; D. S. Greene; U. A. Shukla 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 658 KB

The single-dose pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were examined in 12 healthy younger subjects < 55 years of age (YNG), 12 elderly subjects > 65 years of age (ELD), 12 patients with biopsy proven hepatic cirrhosis